Home  »  Companies   »  Which Institutions Own Shares In Ocular Therapeuti...

Which Institutions Own Shares In Ocular Therapeutix Inc. (OCUL)?

Ocular Therapeutix Inc. (NASDAQ: OCUL) is -40.75% lower on its value in year-to-date trading and has touched a low of $2.91 and a high of $12.50 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The OCUL stock was last observed hovering at around $4.31 in the last trading session, with the day’s loss setting it -0.18% off its average median price target of $15.00 for the next 12 months. It is also 85.76% off the consensus price target high of $29.00 offered by 7 analysts, but current levels are 36.46% higher than the price target low of $6.50 for the same period.

Currently trading at $4.13, the stock is -27.17% and -20.98% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.77 million and changing -4.18% at the moment leaves the stock -16.46% off its SMA200. OCUL registered -60.63% loss for a year compared to 6-month gain of -17.56%.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


The stock witnessed a -19.34% loss in the last 1 month and extending the period to 3 months gives it a 6.17%, and is -28.92% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.74% over the week and 7.45% over the month.

Ocular Therapeutix Inc. (OCUL) has around 228 employees, a market worth around $343.74M and $49.90M in sales. Profit margin for the company is -65.10%. Distance from 52-week low is 41.92% and -66.96% from its 52-week high. The company has generated returns on investments over the last 12 months (-56.00%).

Ocular Therapeutix Inc. (OCUL) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Ocular Therapeutix Inc. (OCUL) is a “Buy”. 7 analysts offering their recommendations for the stock have an average rating of 1.90, where 1 rate it as a Hold and 0 think it is a “Overweight”. 6 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

Ocular Therapeutix Inc. is expected to release its quarterly report on 11/09/2022.The EPS is expected to grow by 96.70% this year

Ocular Therapeutix Inc. (OCUL) Top Institutional Holders

The shares outstanding are 76.76M, and float is at 75.85M with Short Float at 3.83%.

Ocular Therapeutix Inc. (OCUL) Insider Activity

A total of 9 insider transactions have happened at Ocular Therapeutix Inc. (OCUL) in the last six months, with sales accounting for 0 and purchases happening 9 times. The most recent transaction is an insider purchase by SUMMER ROAD LLC, the company’s 10% Owner. SEC filings show that SUMMER ROAD LLC bought 10,000 shares of the company’s common stock on Feb 23 at a price of $4.80 per share for a total of $47986.0. Following the purchase, the insider now owns 5.94 million shares.

Ocular Therapeutix Inc. disclosed in a document filed with the SEC on Feb 18 that SUMMER ROAD LLC (10% Owner) bought a total of 40,000 shares of the company’s common stock. The trade occurred on Feb 18 and was made at $5.00 per share for $0.2 million. Following the transaction, the insider now directly holds 5.93 million shares of the OCUL stock.

Still, SEC filings show that on Jan 28, SUMMER ROAD LLC (10% Owner) acquired 4,023 shares at an average price of $5.20 for $20920.0. The insider now directly holds 5,894,761 shares of Ocular Therapeutix Inc. (OCUL).

Ocular Therapeutix Inc. (OCUL): Who are the competitors?

The company’s main competitors (and peers) include KalVista Pharmaceuticals Inc. (KALV) that is trading -16.38% down over the past 12 months and Anika Therapeutics Inc. (ANIK) that is -39.68% lower over the same period.

Most Popular

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Posts

Receive Best Stock To Trade Before The Opening Bell



100% Free. Stop Anytime. No Spam




The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.